DE NITTO, SIMONE
 Distribuzione geografica
Continente #
NA - Nord America 1.214
AS - Asia 814
EU - Europa 727
SA - Sud America 142
AF - Africa 32
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.935
Nazione #
US - Stati Uniti d'America 1.198
SG - Singapore 379
CN - Cina 163
HK - Hong Kong 151
BR - Brasile 132
IT - Italia 124
RU - Federazione Russa 114
FR - Francia 96
DE - Germania 95
IE - Irlanda 87
SE - Svezia 68
KR - Corea 60
FI - Finlandia 42
GB - Regno Unito 35
ES - Italia 24
TG - Togo 19
BD - Bangladesh 9
CA - Canada 8
PL - Polonia 8
BE - Belgio 7
VN - Vietnam 7
IN - India 6
JP - Giappone 5
LT - Lituania 5
MA - Marocco 5
MX - Messico 5
NL - Olanda 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
ID - Indonesia 4
TR - Turchia 4
UA - Ucraina 4
AT - Austria 3
AZ - Azerbaigian 3
IQ - Iraq 3
IR - Iran 3
JO - Giordania 3
PY - Paraguay 3
AR - Argentina 2
BY - Bielorussia 2
CO - Colombia 2
DZ - Algeria 2
KG - Kirghizistan 2
VE - Venezuela 2
ZA - Sudafrica 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
GH - Ghana 1
IS - Islanda 1
MG - Madagascar 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
PR - Porto Rico 1
RO - Romania 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 2.935
Città #
Chandler 260
Dallas 251
Singapore 195
Hong Kong 151
Ashburn 119
Dublin 84
Beijing 46
Munich 46
Redmond 37
Verona 36
Columbus 33
The Dalles 33
Lawrence 25
Princeton 25
Helsinki 22
Madrid 22
Seattle 21
Sindelfingen 20
Lomé 19
Wilmington 19
Turku 14
New York 12
Seoul 12
São Paulo 12
Los Angeles 11
Moscow 11
Southend 11
Santa Clara 10
Jacksonville 9
Frankfurt am Main 8
Ann Arbor 7
Brussels 7
London 7
Lappeenranta 6
Milan 6
Rome 6
Ancona 5
Bonndorf 5
Boston 5
Brasília 5
Council Bluffs 5
Tashkent 5
Amsterdam 4
Bexley 4
Brooklyn 4
Charlotte 4
Fairfield 4
Mexico City 4
Padova 4
Peschiera del Garda 4
Tokyo 4
Washington 4
Woodbridge 4
Amman 3
Baku 3
Caxias do Sul 3
Curitiba 3
Dhaka 3
Dongguan 3
Hangzhou 3
Levallois-perret 3
Neumünster 3
Norwalk 3
Phoenix 3
Rio de Janeiro 3
San Francisco 3
Shanghai 3
Tappahannock 3
Treviso 3
Vienna 3
Warsaw 3
Wroclaw 3
Agadir 2
Ankara 2
Aracaju 2
Asunción 2
Betim 2
Brescia 2
Cambridge 2
Campinas 2
Caracas 2
Chiuppano 2
Chongqing 2
Denver 2
Dong Ket 2
Erbil 2
Fuzhou 2
Goiânia 2
Guangzhou 2
Haikou 2
Hanoi 2
Hebei 2
Jakarta 2
Krakow 2
Laayoune 2
Marília 2
Minsk 2
Nanjing 2
Ottawa 2
Redwood City 2
Totale 1.800
Nome #
Bile Acids Quantification by Liquid Chromatography-Tandem Mass Spectrometry: Method Validation, Reference Range, and Interference Study 114
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 106
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 103
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 100
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 98
Thrombin Generation in Patients with Coronavirus Disease 2019 97
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 96
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 95
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 91
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 86
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 86
Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay 84
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 79
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 78
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 76
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 72
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 71
Monoclonal gammopathy in SARS-CoV-2 infection 64
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 64
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 63
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 61
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 60
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 60
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 59
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 59
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 59
Impact of water temperature on reconstitution of quality controls for routine hemostasis testing 58
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 57
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 56
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 55
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 55
Cellular immunity against SARS-CoV-2 depends on the serological status 54
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 52
Machine learning model comparison in the screening of cholangiocarcinoma using plasma bile acids profiles 52
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 49
Accuracy of screening for hemolysis in plasma samples using a commercial urine dipstick 48
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 45
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 42
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 41
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 40
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 40
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 37
Impact of the COVID-19 pandemic on the volume of laboratory testing 37
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 35
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 34
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 34
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 30
Totale 3.032
Categoria #
all - tutte 16.132
article - articoli 15.871
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 261
Totale 32.264


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202169 0 0 1 4 9 5 10 2 3 3 5 27
2021/2022228 31 44 7 9 12 7 5 7 17 7 27 55
2022/2023659 37 55 58 120 37 138 23 59 67 9 30 26
2023/2024408 20 30 19 46 61 50 44 64 3 22 39 10
2024/20251.091 59 72 41 165 54 55 34 58 135 98 131 189
2025/2026561 220 189 152 0 0 0 0 0 0 0 0 0
Totale 3.032